An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Ocaliva

Chemical Nameobeticholic acid
Dosage FormTablet (oral; 5 mg, 10 mg)
Drug ClassReceptor agonists
SystemDigestive
CompanyIntercept Pharms Inc
Approval Year2016

Indication

  • For the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Last updated on 12/21/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ocaliva (obeticholic acid) Prescribing Information 2019Intercept Pharmaceuticals, Inc., New York, NY
Document TitleYearSource
Obeticholic acid for treating primary biliary cholangitis.2017NICE
Document TitleYearSource
Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.2020European Journal of Gastroenterology & Hepatology
Treatment of primary biliary cholangitis ursodeoxycholic acid non‐responders: A systematic review. 2017Liver International